Home > Boards > US Listed > Biotechs > MERSANA THERAPEUTICS, INC. (MRSN)

Exactly. Looking forward to pre-clinical on next

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
jaybe Member Profile
 
Followed By 5
Posts 285
Boards Moderated 0
Alias Born 05/29/11
160x600 placeholder
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 9/16/2021 6:02:00 AM
Is Mersana Stock a Buy Right Now? This Is What You Need to Know TipRanks - 9/13/2021 4:20:16 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/10/2021 7:51:32 AM
Mersana Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire Inc. - 9/7/2021 8:00:00 AM
Mersana Therapeutics to Provide Update on the Progress of its UpRi Clinical Development Strategy and Report Interim Data from the Ovarian Cancer Expansion Cohort of the UpRi Phase I Study GlobeNewswire Inc. - 9/1/2021 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/24/2021 4:31:57 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/18/2021 4:32:54 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 8/18/2021 4:31:25 PM
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc. - 8/18/2021 4:05:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/16/2021 8:17:02 AM
Mersana Therapeutics Announces Appointment of Tushar Misra, Ph.D., as Chief Manufacturing Officer GlobeNewswire Inc. - 8/16/2021 8:00:00 AM
Mersana Therapeutics EPS misses by $0.09 Seeking Alpha - 8/6/2021 6:04:38 AM
Mersana Therapeutics Announces Second Quarter 2021 Financial Results and Provides Business Update GlobeNewswire Inc. - 8/6/2021 6:00:00 AM
Mersana Therapeutics to Present at the 12th Annual Wedbush PacGrow Healthcare Conference GlobeNewswire Inc. - 8/4/2021 8:00:00 AM
Mersana Therapeutics to Host Conference Call Announcing Second Quarter 2021 Financial Results and Business Updates GlobeNewswire Inc. - 7/30/2021 8:00:00 AM
Mersana Therapeutics Announces Initiation of the UPGRADE Phase 1 Platinum Combination Cohort for UpRi in Platinum-Sensitive Ovarian Cancer GlobeNewswire Inc. - 7/28/2021 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/2/2021 4:32:28 PM
The Bottom Is in for These 2 Stocks? Analysts Say ‘Buy’ TipRanks - 6/29/2021 11:13:37 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/23/2021 4:31:46 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/17/2021 6:31:32 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/15/2021 6:36:40 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/15/2021 6:04:31 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/15/2021 6:04:16 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/15/2021 6:03:52 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/15/2021 6:02:44 PM
jaybe   Saturday, 05/12/18 04:55:53 PM
Re: dorothy52 post# 17
Post # of 42 
Exactly. Looking forward to pre-clinical on next ADC in November at ENA18.

Also should see next-gen platform (payload/linker) presentation at same conference.

Takeda selected ADC will move more slowly, wouldn't be surprised if we don't see data until next year at AACR19.

All eyes on Wednesday 5PM...first clinical data for XMT-1536, sets the table for all science.

DS-8201 showing 60% ORR in Her2+ and 30% ORR in Her-low, those are the benchmarks for a competitive next-gen ADC in MBC.






Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences